# Sirius Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sirius-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.siriusrna.com
- Total disclosed funding: $110M
- Latest round: Series B (May 9, 2025)
- Investors on record: 5

## About

Based in Shanghai, China, and founded in 2022, Sirius Therapeutics operates as a pharmaceutical R&D service provider, focusing on the development of innovative nucleic acid therapies in the field of cardiovascular diseases. It has set up an innovation research and development center in the USA. The company's CEO, Ji Qunsheng, studied at Vanderbilt University and Peking Union Medical College in the United States. In May 2025, Sirius Therapeutics raised approximately USD 50 million in series B2 funding led by undisclosed investors, with participation from new investor BioTrack Capital, and returning investors OrbiMed Advisors, Creacion Ventures, and Hankang Capital. 

The company focuses on the development of innovative nucleic acid therapies in the field of cardiovascular diseases, and its main products are small nucleic acid drugs. The product pipeline includes SRSD107 injection, SRSD101, and SRSD216. SRSD101 is a PCSK9 siRNA drug, mainly suitable for hypercholesterolemia and atherosclerotic cardiovascular disease. SRSD216 is a siRNA therapy for the treatment of hyperlipoproteinemia (a). Sirius Therapeutics has developed a core technology platform that can be used for the research and development of small nucleic acid drugs. 

The company generates revenue by providing innovative nucleic acid therapies in the field of cardiovascular diseases, such as SRSD107 injection and SRSD101.

The company will use the series B2 funding to advance clinical pipeline progress and enrich product pipelines, accelerating the development of new siRNA therapies.

## Funding rounds

- Series B, May 9, 2025, $50M — OrbiMed Advisors, BioTrack Capital, Hankang Capital, Creacion Ventures
- Series B, Oct 9, 2023, $60M — OrbiMed Advisors, Delos Capital Partners, Hankang Capital, Creacion Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series B
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series B
- Creacion Ventures (https://capitalatlas.ai/funds/creacion-ventures) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B